Here’s Why Supernus Pharmaceuticals, Rent-A-Center and Three Other Stocks are Down Today

Stocks are extending losses on Tuesday, mainly due to healthcare sector, which is down over 2%, and slipping crude prices. The Dow Jones industrial average fell around 170 points, while S&P 500 and NASDAQ down over 1% each.  Among the big losers today include Supernus Pharmaceuticals Inc (NASDAQ:SUPN), Rent-A-Center Inc (NASDAQ:RCII), Msci Inc (NYSE:MSCI), Integrated Device Technology Inc (NASDAQ:IDTI), and IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI). In this article, we will find out why these stocks have tumbled and also analyze the hedge fund sentiment towards them to get a clearer picture.  

We believe that imitating hedge funds and other large institutional investors can be helpful in identifying stocks capable of outperforming the broader market. Through extensive research that covered portfolios of several hundred large investors between 1999 and 2012, we determined that following the small-cap stocks that large money managers are collectively bullish on, can generate monthly returns nearly 1.0 percentage points above the market (see more details here).

Tonis Valing / Shutterstock.com

Supernus Pharmaceuticals Posts Results of ADHD Drug Trial

Supernus Pharmaceuticals Inc (NASDAQ:SUPN)’s stock gained over 5% this morning before going deep in the red after the company announced positive top-line results from its Phase IIb dose-ranging clinical trial of SPN-812 in children for the treatment of attention deficit hyperactivity disorder (ADHD). The trial successfully met its primary endpoint, and achieved “statistically significant” improvement in the symptoms of ADHD, according to a statement released by the Maryland-based pharmaceutical company. However, patients receiving SPN 100 mg had a -16.7 point change from baseline in the primary endpoint and a median effect size of 0.46, which falls short of statistical significance. The company said only two patients experienced three adverse events of severe category, and there were no deaths in the study. A total of 18 funds from our database were long Supernus Pharmaceuticals Inc (NASDAQ:SUPN) at the end of June, down from 24 funds a quarter earlier.

Rent-A-Center Posts Dismal Q3 Estimates

Rent-A-Center Inc (NASDAQ:RCII)’s stock has lost over 29% after the company said it expects third-quarter earnings per share between $0.5 and $0.15, well below the consensus estimate of $0.39. Same-store sales in the US are expected to come in at 12%, while same-store sales for Acceptance Now brand stores are expected to be flat on the year. Rent-A-Center Inc (NASDAQ:RCII)’s CEO Robert Davis said in a statement that the company faced “performance issues” and outages after making a transition to a new point-of-sale system and added that it would take “several quarters” to recover from the effects of the transition. However, Davis is hopeful about the improvement in system performance. At the end of the second quarter, 19 funds tracked by Insider Monkey held stakes in Rent-A-Center Inc (NASDAQ:RCII).

Move on to the next page to read why Msci, Integrated Device Technology and IntelliPharmaCeutics are losing value today. 

Msci Downgraded by Evercore ISI

New York-based investment decision tool provider MSCI Inc (NYSE:MSCI) has slid by around 5% after financial services firm Evercore ISI downgraded the company to ‘Sell’ from ‘Hold’ and updated its price target to $75 from $81, in a report issued to investors on Tuesday. The firm thinks low costs trend in the industry and passive products will put a pressure on MSCI’s licensing fees. The firm also said the competition in the analytics domain is surging, which could impact the company’s margin expansion plans. Anand Desai’s Darsana Capital Partners is one of 23 funds from our database which are bullish on Msci Inc (NYSE:MSCI).

Integrated Device Technology Inc (NASDAQ:IDTI)’s stock is down by over 3.8% on volume above average. The company said on Monday that it will announce its fiscal 2017 second-quarter results on October 31. Analysts expect the company to report earnings of $0.33 per share on revenue of $187.12 million. The stock has lost over 19% so far this year. As of the end of the June quarter, 26 funds in our database own shares of Integrated Device Technology Inc (NASDAQ:IDTI).

IntelliPharmaCeutics Paring Gains

IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI)’s investors are in profit-taking mode today after yesterday’s big gains. The stock is down over 7% so far. The Canadian pharmaceutical company announced on Friday it received a tentative FDA approval for its abbreviated new drug application (ANDA) for quetiapine fumarate extended-release tablets. The drug is a generic equivalent for Seroquel XR, which is sold in the US by Astra Zeneca Pharmaceuticals, which has permitted IntelliPharmaCeutics to sell generic versions of the 50, 150, 200, 300 and 400 mg strengths of Seroquel XR after the final FDA approval. Ken Griffin’s Citadel Investment Group owns 14,492 shares of the company as of the end of June.

Disclosure: none